Difference in in vitro cytotoxicity toward A2780 and drug-resistant A2780cis and A2780adr Table S2 Relative toxicity of 1-3 and Au1a toward cancer cells and NCM460 cells Table S3 Relative toxicity of 1-3 and Au1a toward cancer cells and MIHA cells Table S4 Relative toxicity of 1-3 and Au1a toward cancer cells and CCD-19Lu cells Table S5 In vitro cytotoxicity of 1, 3 and cisplatin toward non-tumorigenic liver L02 and gliocyte CHEM-5 cells Table S7 Relative toxicity of DOX toward cancer cells and NCM460 cells through administration of DOX alone and administration by NC1 fetal bovine serum, ʟ-glutamine (2 mM) and penicillin/streptomycin (100 U/mL).
Cisplatin-and adriamycin-resistant derivatives of A2780 (A2780cis and A2780adr)
were maintained in RPMI-1640 medium with 10 vol% fetal bovine serum, ʟ-glutamine (2 mM) and penicillin/streptomycin (100 U/mL) as well as cisplatin (1 µM) and doxorubicin (0.1 µM), respectively. Non-tumorigenic immortalized liver cells (MIHA), human normal liver cells (L02) and human normal gliocyte cells were maintained in Dulbecco's modified Eagle's medium with 10 vol% fetal bovine serum, ʟ-glutamine (2 mM) and penicillin/streptomycin (100 U/mL). Cells were incubated in 5% CO 2 humidified air, and subcultured when 80% confluence was reached.
Physical measurements and instrumentation. 1 H NMR spectra were recorded with 
[Au(TPP-CONH-PEG 5000 -OCH 3 )]Cl (2)
The procedure was similar to that for complex 1, except that H 3 CO-PEG 5000 -NH 2 •HCl (124 mg, 0.025 mmol) was used instead of HO-PEG 5000 -OCH 3 . The red solid obtained after precipitation was further purified by column chromatography on neutral alumina, using dichloromethane and methanol (50: Preparation of nanocomposites of 1 and DOX. The procedure was similar to that of the preparation of nanostructures of 1, except that both complex 1 (2.5 mg) and DOX were dissolved in the acetonitrile (0.5 mL).
P.7
The gold content of the nanocomposites was determined by dissolving the nanocomposites in conc. HNO 3 / conc. HCl solution mixture (9:1, v/v; 30 µL), followed by ICP-MS analysis.
The content of DOX in the nanocomposites was measured as follows. The nanocomposite (10 µL) was dissolved in acetonitrile (90 µL), and subjected to gentle shaking overnight. The solution mixture was then dried under vacuum, and redispersed in 0.1 vol% formic acid in water/acetonitrile (7/3, v/v; 1 mL) solution mixture. The solution was then diluted and filtered, and the content of DOX in the nanocomposite was determined by UPLC with photodiode array detector using daunorubicin hydrochloride (3.6 µM) as the internal standard. The mobile phase was 0.1 vol% formic acid in water/acetonitrile ( respectively, were sacrificed and tissues including liver, spleen, lung, kidney and heart were harvested. The tissues were digested with 10% HCl in concentrated HNO 3 (0.1 g of tissue/1 mL). The solution mixture was heated at 60 o C for 15 h, and then diluted 50 times by ultra-pure water for ICP-MS analysis.
Determination of in vivo biodistribution of complex 1, 3 and Au1a by ICP-MS.
Nude mice bearing HCT116 xenografts were treated with 1 (13 mg/kg), or equal molar amount of Au1a (2 mg/kg) or 3 (2 mg/kg) through intravenous injection. After 24 h of the injection, the mice were sacrificed and tissues from tumor, liver, spleen, lung, kidney and heart were harvested. The tissues were digested with 10% HCl in concentrated HNO 3 (0.1 g of tissue/1 mL). The solution mixture was heated at 60 o C for 15 h, and then diluted 50 times by ultra-pure water for ICP-MS analysis.
Analysis of tumor tissue from mice treated with complexes 1 by UPLC-QTOF-

MS.
At the end point of tumor growth inhibition study, the mice treated with solvent control or complex 1 were sacrificed and the tumor tissues were harvested, followed by homogenization in 50% ice-cold acetonitrile (0.1 g/300 µL). Time / min 
